B. Metzler seel. Sohn & Co. Holding AG Acquires New Position in HealthEquity, Inc. (NASDAQ:HQY)

B. Metzler seel. Sohn & Co. Holding AG bought a new position in HealthEquity, Inc. (NASDAQ:HQY) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 69,339 shares of the company’s stock, valued at approximately $5,675,000. B. Metzler seel. Sohn & Co. Holding AG owned approximately 0.08% of HealthEquity at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC purchased a new stake in shares of HealthEquity in the second quarter valued at about $35,000. Paladin Wealth LLC purchased a new stake in shares of HealthEquity in the 3rd quarter valued at approximately $39,000. GAMMA Investing LLC increased its holdings in shares of HealthEquity by 114.8% during the 2nd quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock worth $51,000 after buying an additional 318 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of HealthEquity during the 2nd quarter valued at approximately $73,000. Finally, 1620 Investment Advisors Inc. purchased a new stake in shares of HealthEquity during the 3rd quarter valued at approximately $112,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other HealthEquity news, Director Frank Corvino sold 1,039 shares of HealthEquity stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the completion of the sale, the director now directly owns 3,784 shares of the company’s stock, valued at $363,642.40. The trade was a 21.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert W. Selander sold 8,250 shares of the stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the transaction, the director now owns 54,719 shares in the company, valued at approximately $4,540,582.62. The trade was a 13.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock worth $884,517 in the last 90 days. Corporate insiders own 2.20% of the company’s stock.

HealthEquity Trading Up 0.3 %

NASDAQ:HQY opened at $102.67 on Wednesday. HealthEquity, Inc. has a 12-month low of $62.10 and a 12-month high of $103.12. The firm has a market cap of $8.97 billion, a PE ratio of 85.56, a price-to-earnings-growth ratio of 1.55 and a beta of 0.52. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. The stock has a fifty day moving average price of $86.10 and a 200 day moving average price of $81.42.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The business had revenue of $299.93 million during the quarter, compared to analysts’ expectations of $284.48 million. Sell-side analysts anticipate that HealthEquity, Inc. will post 2.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HQY has been the subject of several recent analyst reports. JMP Securities reissued a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. BTIG Research boosted their price objective on shares of HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft upped their target price on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Barrington Research reiterated an “outperform” rating and set a $105.00 price target on shares of HealthEquity in a research report on Friday, September 20th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $92.00 price objective on shares of HealthEquity in a research report on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $107.23.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.